Fortress Biotech, Inc. APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition
Fortress Biotech, Inc. (FBIO) reported APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition of $13.90 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-18.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition · last filed 2019-03-18
- Fortress Biotech, Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2018 was $13.90M, a 23.01% increase from fiscal 2017.
- Fortress Biotech, Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2017 was $11.30M, a 14.14% increase from fiscal 2016.
- Fortress Biotech, Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2016 was $9.90M, a 43.48% increase from fiscal 2015.
- Fortress Biotech, Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2015 was $6.90M, a 72.50% increase from fiscal 2014.
| Period end | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 90 month |
|---|---|---|
| 2018-12-31 | $13.90M 10-K · filed 2019-03-18 | |
| 2017-12-31 | $11.30M 10-K · filed 2019-03-18 | |
| 2016-12-31 | $9.90M 10-K · filed 2018-03-16 | |
| 2015-12-31 | $6.90M 10-K · filed 2018-03-16 | |
| 2014-12-31 | $4.00M 10-K · filed 2017-03-16 | |
| 2013-12-31 | $66.00K 10-K · filed 2016-03-15 | $2.20M 10-K · filed 2014-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |